Between 10 and 15% of breast tumors are classified as triple-negative breast cancer (TNBC), characterized by negative expression of the estrogen- (ER), progesterone- (PR), and human epidermal growth factor receptor 2 (HER2) receptors. Here, ERBB2 is linked to breast neoplasm.